zileuton has been researched along with dinoprostone in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (25.00) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Bukhave, K; Lauritsen, K; Laursen, LS; Naesdal, J; Rask-Madsen, J | 1 |
| Cohn, J; Dworski, R; Fish, JE; Kane, GC; Kim, CJ; Murray, JJ; Peters, SP; Pollice, M; Sheller, J; Tollino, M | 1 |
| Kotadia, B; Mangino, JE; Mangino, MJ; Sielczak, M | 1 |
| Hardy, DB; Pereria, LE; Yang, K | 1 |
| Harada, K; Inoue, T; Nagakura, N; Oketani, K | 1 |
| Alcaraz, MJ; Guillén, MI; Vicente, AM | 1 |
| Beer, DG; Chen, X; Giordano, TJ; Jin, Z; Lin, Y; Lubet, RA; Shih, WC; Sood, S; Wang, P; Wang, S; Wu, N; Yang, CS | 1 |
| Gregor, JI; Heukamp, I; Jacobi, CA; Kiewert, C; Kilian, M; Kristiansen, G; Schimke, I; Walz, MK; Wenger, FA | 1 |
| Kulkarni, SK; Kumar, M; Patil, CS; Singh, VP | 1 |
| Bramanti, P; Caminiti, R; Cuzzocrea, S; Di Paola, R; Genovese, T; Mazzon, E; Muià, C; Rossi, A; Sautebin, L | 1 |
| Hu, JH; Li, FQ; Liu, JY; Liu, YX; Pan, YH; Peng, C; Wang, XR; Wu, L; Xu, JG; You, BM; Zhu, QG; Zhu, Y | 1 |
| Choi, HE; Kwak, HJ; Lim, HJ; Park, HY; Park, JH; Park, KM | 1 |
| Bramanti, P; Cuzzocrea, S; Dehm, F; Hoffmann, M; Koeberle, A; Pergola, C; Rossi, A; Sautebin, L; Werz, O | 1 |
| Altavilla, D; Arcoraci, V; Bitto, A; Galfo, F; Irrera, N; Macrì, A; Minutoli, L; Pallio, G; Pizzino, G; Squadrito, F; Squadrito, G | 1 |
1 trial(s) available for zileuton and dinoprostone
| Article | Year |
|---|---|
Insights into IgE-mediated lung inflammation derived from a study employing a 5-lipoxygenase inhibitor.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Bronchial Provocation Tests; Bronchoalveolar Lavage Fluid; Bronchoscopy; Cross-Over Studies; Dinoprost; Dinoprostone; Double-Blind Method; Eosinophils; Humans; Hydroxyurea; Leukotriene B4; Leukotriene E4; Leukotrienes; Lipoxygenase Inhibitors; Lung; Lung Injury; Placebos; Prostaglandin D2; Prostaglandin-Endoperoxide Synthases; Proteins; Regression Analysis; Respiratory Hypersensitivity; Thromboxane B2 | 1995 |
15 other study(ies) available for zileuton and dinoprostone
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Selective 5-lipoxygenase inhibition in ulcerative colitis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arachidonate Lipoxygenases; Colitis, Ulcerative; Dialysis; Dinoprostone; Drug Evaluation; Humans; Hydroxyurea; Leukotriene B4; Lipoxygenase Inhibitors; Middle Aged; Recurrence; Time Factors | 1990 |
Effects of the 5-lipoxygenase inhibitor A-64077 on intestinal hypothermic organ preservation injury.
Topics: Animals; Cryopreservation; Dinoprostone; Dogs; Hydroxyurea; Ileum; Leukotriene B4; Lipoxygenase Inhibitors; Organ Preservation; Peroxidase | 1997 |
Prostaglandins and leukotriene B4 are potent inhibitors of 11beta-hydroxysteroid dehydrogenase type 2 activity in human choriocarcinoma JEG-3 cells.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Choriocarcinoma; Dinoprost; Dinoprostone; Enzyme Inhibitors; Humans; Hydroxysteroid Dehydrogenases; Hydroxyurea; Indomethacin; Isoenzymes; Leukotriene B4; Lipoxygenase Inhibitors; Masoprocol; Placenta; Prostaglandins; Tumor Cells, Cultured | 1999 |
In vitro effects of E3040, a dual inhibitor of 5-lipoxygenase and thromboxane A(2) synthetase, on eicosanoid production.
Topics: Animals; Arachidonate 5-Lipoxygenase; Benzothiazoles; Dinoprostone; Dose-Response Relationship, Drug; Eicosanoids; Humans; Hydroxyurea; Indomethacin; Leukocytes; Leukotriene B4; Lipoxygenase Inhibitors; Male; Mesalamine; Methacrylates; Neutrophils; Peritoneal Cavity; Prostaglandin-Endoperoxide Synthases; Pyridines; Rats; Rats, Inbred F344; Sheep; Sulfasalazine; Thiazoles; Thromboxane B2; Thromboxane-A Synthase | 2001 |
Modulation of haem oxygenase-1 expression by nitric oxide and leukotrienes in zymosan-activated macrophages.
Topics: Amidines; Animals; Benzylamines; Cell Line; Chick Embryo; Cyclooxygenase 2; Dexamethasone; Dinoprostone; Dose-Response Relationship, Drug; Eicosanoids; Enzyme Inhibitors; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Hydroxyurea; Indomethacin; Isoenzymes; Leukotriene B4; Leukotriene C4; Leukotrienes; Macrophage Activation; Macrophages; NF-kappa B; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitrites; Nitrobenzenes; Prostaglandin-Endoperoxide Synthases; Protein Binding; Pyrans; Quinolones; Sulfonamides; Time Factors; Transcription Factor AP-1; Zymosan | 2001 |
Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis.
Topics: Adenocarcinoma; Anastomosis, Surgical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Body Weight; Celecoxib; Dinoprostone; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Esophageal Neoplasms; Humans; Hydroxyurea; Immunohistochemistry; Leukotriene B4; Lipoxygenase Inhibitors; Male; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Time Factors | 2004 |
Effects of selective COX-2 and 5-LOX inhibition on prostaglandin and leukotriene synthesis in ductal pancreatic cancer in Syrian hamster.
Topics: Animals; Carcinoma, Pancreatic Ductal; Celecoxib; Cricetinae; Cyclooxygenase Inhibitors; Dinoprostone; Drug Therapy, Combination; Hydroxyurea; Leukotrienes; Lipoxygenase Inhibitors; Liver; Liver Neoplasms; Pancreas; Pancreatic Neoplasms; Prostaglandins; Prostaglandins F; Pyrazoles; Sulfonamides | 2005 |
Effect of 5-lipoxygenase inhibitor against lipopolysaccharide-induced hypothermia in mice.
Topics: Animals; Colon; Dinoprostone; Female; Hydroxyurea; Hypothalamus; Hypothermia; Hypothermia, Induced; Indomethacin; Leukotriene B4; Leukotrienes; Lipopolysaccharides; Lipoxygenase Inhibitors; Male; Mice | 2005 |
Effects of zileuton and montelukast in mouse experimental spinal cord injury.
Topics: Acetates; Animals; Apoptosis; Arachidonate 5-Lipoxygenase; Cyclooxygenase 2; Cyclopropanes; Cysteine; Dinoprostone; Disease Models, Animal; Gene Expression Regulation; Hydroxyurea; Inflammation; Leukotrienes; Lipoxygenase Inhibitors; Male; Mice; Neutrophil Infiltration; Quinolines; Recovery of Function; Spinal Cord Injuries; Sulfides; Tumor Necrosis Factor-alpha | 2008 |
Induction of leukotriene B(4) and prostaglandin E(2) release from keratinocytes by protease-activated receptor-2-activating peptide in ICR mice.
Topics: Animals; Cetirizine; Dinoprostone; Dose-Response Relationship, Drug; Drug Interactions; Hydroxyurea; Indomethacin; Injections, Intradermal; Keratinocytes; Leukotriene B4; Male; Mice; Mice, Inbred ICR; Oligopeptides; Pruritus; Skin; Tacrolimus | 2009 |
The cardioprotective effects of zileuton, a 5-lipoxygenase inhibitor, are mediated by COX-2 via activation of PKC delta.
Topics: Animals; Animals, Newborn; Apoptosis; Cell Survival; Cells, Cultured; Cyclooxygenase 2; Cytoprotection; Dinoprostone; Enzyme Activation; Hydrogen Peroxide; Hydroxyurea; Lipoxygenase Inhibitors; MAP Kinase Signaling System; Myocytes, Cardiac; Protein Kinase C-delta; Rats | 2010 |
The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages.
Topics: Animals; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Carrageenan; Cyclooxygenase 2; Dinoprostone; Disease Models, Animal; Humans; Hydroxyurea; Interferon-gamma; Intramolecular Oxidoreductases; Lipopolysaccharides; Lipoxygenase Inhibitors; Macrophages; Mice; Mice, Inbred Strains; Pleurisy; Prostaglandin-E Synthases; Prostaglandins F; Rats; Rats, Wistar; Zymosan | 2010 |
Use of a balanced dual cyclooxygenase-1/2 and 5-lypoxygenase inhibitor in experimental colitis.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Apoptosis; Arachidonate 5-Lipoxygenase; Body Weight; Catechin; CD3 Complex; Celecoxib; Colitis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Combinations; Eating; Gene Expression Regulation; Hydroxyurea; Leukotriene B4; Lipid Peroxidation; Lipoxygenase Inhibitors; Male; Neutrophil Infiltration; Rats; Rats, Sprague-Dawley; Thromboxane B2; Tumor Necrosis Factor-alpha | 2016 |